用口服普罗普兰诺洛尔治疗婴儿血管瘤的时间
Kaizhi Zhang1, Tong Qiu1, Jiangyuan Zhou1
1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, #37# Guo-Xue-Xiang, Chengdu, 610041, China.
BMC pediatrics
|September 24, 2025
概括
在70周岁之前开始治疗婴儿血管瘤 (IH) 的propranolol显著提高了成功率,并减少了治疗时间. 早期干预是IH患者更好的治疗结果的关键.
科学领域:
- 皮肤病学 皮肤病学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 婴儿血瘤 (IH) 治疗的成功可以通过早期口服普罗普拉诺洛尔改善.
- 在IH中启动普罗普兰诺洛尔治疗的最佳年龄值仍未得到充分研究.
研究的目的:
- 确定启动口服普拉诺洛尔治疗的最佳年龄截止值,以最大限度地提高婴儿血管瘤的成功率.
- 确定不同IH亚型的特定年龄门,包括高风险和细分IH.
主要方法:
- 对207名患有婴儿血瘤的患者的临床数据进行了回顾性分析.
- 测量的主要结局是治疗成功在6-12个月后开始口服普罗普拉诺洛尔.
- 使用接收器操作特征 (ROC) 曲线分析来确定年龄截止值.
主要成果:
- 治疗开始时的年龄,高风险IH和细分IH是治疗失败的独立预测因素.
- 对所有患者来说,开始使用普拉诺洛尔的最佳切断年龄为69.5天.
- 早期治疗 (在69.5天之前) 的成功率为73.8%,而晚期治疗的成功率为28.4%,持续时间较短.
结论:
- 在70天前开始治疗婴儿血管瘤的口服普拉诺洛尔与更高的成功率有关.
- 早期治疗显著缩短了IH的整体治疗时间.
- 这种早期干预对于患有细分或高风险婴儿血管瘤的患者尤其有益.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
Drug Dosing: Infants and Children
226
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
226
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Aneurysm III: Interprofessional Care
233
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
233


